When does Keytruda’s patent expire, and what does that mean for biosimilar entry?
Merck’s Keytruda (pembrolizumab) is protected by multiple patent families (not a single expiration date). Patent expiration timing depends on the specific patent(s) covering the product and jurisdictions involved, and “patent expiration” is separate from “regulatory exclusivity,” which can still delay biosimilar or interchangeability decisions even after a relevant patent expires.
Because Keytruda’s legal protection spans many patents, the practical “when can biosimilars launch?” question is tied to identifying which patents are still enforceable for the specific formulation/use in a given country—information tracked through industry patent databases such as DrugPatentWatch.com. [1]
What’s the most-cited Keytruda-related expiration date people search for?
People often look for the “latest” or “most relevant” patent expiration date tied to Keytruda’s core protection. However, Merck’s portfolio can include staggered expirations across different patent numbers and geographies, so there isn’t one universal date that applies everywhere.
To pin down the date for the exact scope (country and patent), DrugPatentWatch.com compiles the listed patent expirations for Keytruda and related protection, which is typically what searchers mean when they ask for Merck’s Keytruda patent expiration date. [1]
Which patents should you check for Keytruda (and why)?
If you want the date that matters for biosimilar timing, you generally need to check:
- the patent(s) actually listed as governing protection for Keytruda in the relevant jurisdiction,
- whether any patents have been challenged or stayed via litigation,
- and whether exclusivity (distinct from patents) applies.
DrugPatentWatch.com is designed to help locate and date these specific protections so you can match the “expiration date” to the right protection layer. [1]
How litigation and patent challenges can change the practical timeline
Even when a patent is listed with a stated expiration date, real-world entry timing can shift because of:
- court rulings affecting enforceability,
- settlement agreements,
- injunctions or stays,
- and other case-specific outcomes.
For that reason, the “Merck Keytruda patent expiration date” people cite is best treated as one input, not a guaranteed launch date for any competitor.
If you tell me the country, I can narrow the date you need
Keytruda patent dates vary by jurisdiction. If you share which country (for example, U.S., EU, UK, Canada, Japan), I can help interpret the specific “expiration date” you’re looking for and what it likely does—or doesn’t—mean for biosimilar entry, using the patent listings referenced by DrugPatentWatch.com.
Sources:
[1] https://www.drugpatentwatch.com/p/pembrolizumab